Reading this on a mobile device? Try our optimized mobile version here:

November 6, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • Only a few can access Amyvid PET scans
    The FDA in April approved Amyvid, a PET imaging agent for Alzheimer's disease, but only a few people are getting the scans because the federal government and private insurers are not covering it. In the U.S., only about 300 practices or hospitals are offering the scans or are planning to in the near future, said Morry Smulevitz of Amyvid maker Lilly Bio-Medicines. CMS said it is reviewing potential coverage for the scans. The process could take a year, Smulevitz said. The Columbus Dispatch (Ohio) (11/5) LinkedInFacebookTwitterEmail this Story
The MEDRAD™ Intego™ is making personalized PET practical.
Clinicians are able to set weight-based dosing formulas to determine and administer a personalized minimum acceptable dose for each unique patient. Precise delivery and dose-on-demand capabilities enable lower patient dosing, leading to better patient care. To learn more, click here.
  Clinical News & Research 
  • Study: Anti-TNF-alpha therapy aids patients with RA
    Patients with rheumatoid arthritis manifest a subclinical vasculitis that may be linked to a higher risk of cardiovascular disease, and using anti-tumor necrosis factor alpha therapy may lessen this risk, researchers write in an editorial in Circulation. The researchers used F-FDG-PET/CT to determine vascular inflammation in patients. "Our data suggest that vascular inflammation could underpin the mechanism of increased CVD in RA, and also demonstrates that PET/CT scanning could be a useful tool for CVD risk stratification and for monitoring risk reduction of anti-inflammatory therapies in patients with chronic inflammatory diseases," according to the team. News-Medical.Net/medwireNews (11/5) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Novelos gets funding for LIGHT facility
    Novelos Therapeutics said it has secured $2 million from a Russian investor, an affiliate of Renova Group. The company will use the money to establish a production facility for its molecular cancer imaging agent I-124-CLR1404, also called LIGHT. The facility is set to be finished in one year. Wisconsin State Journal (Madison) (11/5) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Group gives tips on how to improve breast density notification
    The American Society of Breast Disease has released a statement with recommendations on how physicians can improve breast density notification for women. The recommendations include communicating the information in a way that women can comprehend and practicing shared decision-making. "If women know their lifetime risk ... and whether or not their breasts are dense, they will be better equipped to understand the recommendations their physicians make -- and make more informed screening decisions," the group said. (free registration) (11/5) LinkedInFacebookTwitterEmail this Story
  International Developments 
  Health Policy 
  • Premier calls device ID rule the "missing link" to patient safety
    The FDA's proposal to create a unique device identifier system to electronically track medical technologies has earned support from the Premier Healthcare Alliance, which said it will enhance adverse event reporting and make product recalls faster and more accurate. The move also could save the industry about $16 billion a year due to increased efficiencies, the group said. Healthcare Informatics online (11/2) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Group injects Alzheimer's funding into the political discourse
    The Alzheimer's Association is mobilizing volunteers to attend political campaign events to get the candidates to talk about funding for Alzheimer's disease research. "We can either keep ignoring it with no treatment and no cure, and the majority of those costs will be paid by Medicaid and Medicare, or we can start funding research to find a cure," volunteer April Holden said. Roll Call (free content) (11/1) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
  • Tributes to Henry N. Wagner, Jr., MD
    SNMMI is collecting thoughts, stories, videos and photos — both professional and personal — from our members to remember Dr. Wagner, both on the SNMMI website and at the SNMMI Annual Meeting in June. More information. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

It's impossible to move, to live, to operate at any level without leaving traces, bits, seemingly meaningless fragments of personal information."
--William Gibson,
American-Canadian author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.®  Legal Information